UK’s NICE probably won’t cover Tasigna, Spycel, and high-dose Gleevec in second-line CML (following progression on regular-dose Gleevec): http://www.bloomberg.com/news/2011-05-05/bristol-myers-novartis-cancer-drugs-are-under-u-k-cost-review.html